[{"indications": "Indications\u00a0uncomplicated premature labour (\n(From 7.1.3 Myometrial relaxants: British National Formulary)\nA beta2 agonist (salbutamol or terbutaline) is used for inhibiting uncomplicated premature labour between 24 and 33 weeks of gestation and it may permit a delay in delivery of at least 48 hours. Prolonged therapy should be avoided since risk to the mother increases after 48 hours and there is a lack of evidence of benefit from further treatment; maintenance treatment is therefore not recommended.); asthma\r\n(%s\n(From 3.1.1 Adrenoceptor agonists: British National Formulary)\n3.1.1 Adrenoceptor agonists)", "name": "TERBUTALINE SULPHATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "7 Obstetrics, gynaecology, and urinary-tract disorders", "7.1 Drugs used in obstetrics", "7.1.3 Myometrial relaxants", "Beta2 agonists", "TERBUTALINE SULPHATE"], "cautions": "Cautions\u00a0\n(From Beta2 agonists: British National Formulary)\nCautions\u00a0Beta2 agonists should be used with caution in patients with suspected cardiovascular disease (such patients should be assessed by a cardiologist before initiating therapy\u2014see also Contra-indications, below), hypertension, mild to moderate pre-eclampsia, hyperthyroidism, and hypokalaemia (particular risk with potassium-depleting diuretics\u2014see also Hypokalaemia). It is important to monitor pulse rate (should not exceed 140 beats per minute), ECG (discontinue treatment if signs of myocardial ischaemia develop), and the patient\u2019s fluid and electrolyte status (avoid over-hydration\u2014discontinue drug immediately and initiate diuretic therapy if pulmonary oedema occurs). Beta2 agonists should also be used with caution in diabetes\u2014monitor blood glucose (risk of hyperglycaemia and ketoacidosis, especially with intravenous beta2 agonists).; interactions: Appendix 1 (sympathomimetics, beta2)", "side-effects": "Side-effects\u00a0\n(From Beta2 agonists: British National Formulary)\nSide-effects\u00a0 Side-effects of the beta2 agonists include nausea, vomiting, pulmonary oedema (see Cautions above), palpitation, tachycardia, arrhythmias, myocardial ischaemia, peripheral vasodilation, headache, tremor, hyperglycaemia, hypokalaemia (see Cautions), muscle cramps and tension, and hypersensitivity reactions (including angioedema, urticaria, rash, bronchospasm, hypotension, and collapse).; also\r\nreported sleep disturbances and behavioural disturbances", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/104941.htm", "doses": ["By intravenous infusion, 5\u00a0micrograms/minute\r\nfor 20 minutes, increased every 20 minutes in steps of 2.5\u00a0micrograms/minute\r\nuntil contractions have ceased (more than 10\u00a0micrograms/minute should seldom be given\u201420\u00a0micrograms/minute should not be exceeded), continue for 1 hour then decrease every 20 minutes\r\nin steps of 2.5\u00a0micrograms/minute to lowest dose that maintains suppression,\r\ncontinue at this level for 12 hours then by mouth (but\r\nsee notes above), 5\u00a0mg every 8 hours for as long as is desirable to\r\nprolong pregnancy (or alternatively follow the intravenous infusion by subcutaneous injection 250\u00a0micrograms every 6 hours for\r\na few days then by mouth as above)"]}, {"indications": "Indications\u00a0uncomplicated premature labour (\n(From 7.1.3 Myometrial relaxants: British National Formulary)\nA beta2 agonist (salbutamol or terbutaline) is used for inhibiting uncomplicated premature labour between 24 and 33 weeks of gestation and it may permit a delay in delivery of at least 48 hours. Prolonged therapy should be avoided since risk to the mother increases after 48 hours and there is a lack of evidence of benefit from further treatment; maintenance treatment is therefore not recommended.); asthma\r\n(%s\n(From 3.1.1 Adrenoceptor agonists: British National Formulary)\n3.1.1 Adrenoceptor agonists)", "name": "TERBUTALINE SULPHATE - BETA2 AGONISTS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "7 Obstetrics, gynaecology, and urinary-tract disorders", "7.1 Drugs used in obstetrics", "7.1.3 Myometrial relaxants", "Beta2 agonists", "TERBUTALINE SULPHATE"], "cautions": "Cautions\u00a0\n(From Beta2 agonists: British National Formulary)\nCautions\u00a0Beta2 agonists should be used with caution in patients with suspected cardiovascular disease (such patients should be assessed by a cardiologist before initiating therapy\u2014see also Contra-indications, below), hypertension, mild to moderate pre-eclampsia, hyperthyroidism, and hypokalaemia (particular risk with potassium-depleting diuretics\u2014see also Hypokalaemia). It is important to monitor pulse rate (should not exceed 140 beats per minute), ECG (discontinue treatment if signs of myocardial ischaemia develop), and the patient\u2019s fluid and electrolyte status (avoid over-hydration\u2014discontinue drug immediately and initiate diuretic therapy if pulmonary oedema occurs). Beta2 agonists should also be used with caution in diabetes\u2014monitor blood glucose (risk of hyperglycaemia and ketoacidosis, especially with intravenous beta2 agonists).; interactions: Appendix 1 (sympathomimetics, beta2)", "side-effects": "Side-effects\u00a0\n(From Beta2 agonists: British National Formulary)\nSide-effects\u00a0 Side-effects of the beta2 agonists include nausea, vomiting, pulmonary oedema (see Cautions above), palpitation, tachycardia, arrhythmias, myocardial ischaemia, peripheral vasodilation, headache, tremor, hyperglycaemia, hypokalaemia (see Cautions), muscle cramps and tension, and hypersensitivity reactions (including angioedema, urticaria, rash, bronchospasm, hypotension, and collapse).; also\r\nreported sleep disturbances and behavioural disturbances", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/104941.htm", "doses": ["By intravenous infusion, 5\u00a0micrograms/minute\r\nfor 20 minutes, increased every 20 minutes in steps of 2.5\u00a0micrograms/minute\r\nuntil contractions have ceased (more than 10\u00a0micrograms/minute should seldom be given\u201420\u00a0micrograms/minute should not be exceeded), continue for 1 hour then decrease every 20 minutes\r\nin steps of 2.5\u00a0micrograms/minute to lowest dose that maintains suppression,\r\ncontinue at this level for 12 hours then by mouth (but\r\nsee notes above), 5\u00a0mg every 8 hours for as long as is desirable to\r\nprolong pregnancy (or alternatively follow the intravenous infusion by subcutaneous injection 250\u00a0micrograms every 6 hours for\r\na few days then by mouth as above)"]}, {"indications": "Indications\u00a0asthma and other conditions associated with reversible\r\nairways obstruction; premature labour (section 7.1.3)", "name": "TERBUTALINE SULPHATE - SELECTIVE BETA2 AGONISTS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "3 Respiratory system", "3.1 Bronchodilators", "3.1.1 Adrenoceptor agonists", "3.1.1.1 Selective beta2 agonists", "TERBUTALINE SULPHATE"], "cautions": "Cautions\u00a0\n(From 3.1.1.1 Selective beta2 agonists: British National Formulary)\nCautions\u00a0Beta2 agonists should be used with caution in hyperthyroidism, cardiovascular disease, arrhythmias, susceptibility to QT-interval prolongation, and hypertension. Beta2 agonists should be used with caution in diabetes\u2014monitor blood glucose (risk of ketoacidosis, especially when beta2 agonist given intravenously). Interactions: Appendix 1 (sympathomimetics, beta2).Hypokalaemia\u00a0Potentially serious hypokalaemia may result from beta2 agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, and diuretics, and by hypoxia. Plasma-potassium concentration should therefore be monitored in severe asthma.", "side-effects": "Side-effects\u00a0\n(From 3.1.1.1 Selective beta2 agonists: British National Formulary)\nSide-effects\u00a0Side-effects of the beta2 agonists include fine tremor (particularly in the hands), nervous tension, headache, muscle cramps, and palpitation. Other side-effects include tachycardia, arrhythmias, peripheral vasodilation, myocardial ischaemia, and disturbances of sleep and behaviour. Paradoxical bronchospasm (occasionally severe), urticaria, angioedema, hypotension, and collapse have also been reported. High doses of beta2 agonists are associated with hypokalaemia (see Hypokalaemia above).", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2897.htm", "doses": ["By mouth (but use by inhalation preferred),\r\ninitially 2.5\u00a0mg 3 times daily for 1\u20132 weeks, then up to 5\u00a0mg 3 times\r\ndaily; child 1 month\u20137 years 75\u00a0micrograms/kg\r\n3 times daily; 7\u201315 years 2.5\u00a0mg 2\u20133 times daily", "By subcutaneous or slow intravenous injection, 250\u2013500\u00a0micrograms up\r\nto 4 times daily; child 2\u201315 years\r\n10\u00a0micrograms/kg to a max. of 300\u00a0micrograms", "By continuous intravenous infusion as a solution containing 3\u20135\u00a0micrograms/mL, 90\u2013300\u00a0micrograms/hour\r\nfor 8\u201310 hours; child 1 month\u201318 years,\r\ninitially 2\u20134\u00a0micrograms/kg as a loading dose, then 1\u201310\u00a0micrograms/kg/hour\r\naccording to response and heart rate (max. 300\u00a0micrograms/hour); high\r\ndoses with close monitoring", "By inhalation of powder (Turbohaler\u00ae), adult and child over 5 years, 500\u00a0micrograms (1 inhalation);\r\nfor persistent symptoms up to 4 times daily (but see Management of Chronic Asthma\r\ntable)", "By inhalation of nebulised solution (but see also Management of Acute Asthma table), 5\u201310\u00a0mg 2\u20134 times daily;\r\nadditional doses may be necessary in severe acute asthma; child under 5 years 5\u00a0mg 2\u20134 times daily, 5\u201312 years\r\n5\u201310\u00a0mg 2\u20134 times daily [unlicensed dose]"], "pregnancy": "Pregnancy\u00a0see section 3.1"}, {"indications": "Indications\u00a0asthma and other conditions associated with reversible\r\nairways obstruction; premature labour (section 7.1.3)", "name": "TERBUTALINE SULPHATE Oral and parenteral", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "3 Respiratory system", "3.1 Bronchodilators", "3.1.1 Adrenoceptor agonists", "3.1.1.1 Selective beta2 agonists", "TERBUTALINE SULPHATE", "Oral and parenteral"], "cautions": "Cautions\u00a0\n(From 3.1.1.1 Selective beta2 agonists: British National Formulary)\nCautions\u00a0Beta2 agonists should be used with caution in hyperthyroidism, cardiovascular disease, arrhythmias, susceptibility to QT-interval prolongation, and hypertension. Beta2 agonists should be used with caution in diabetes\u2014monitor blood glucose (risk of ketoacidosis, especially when beta2 agonist given intravenously). Interactions: Appendix 1 (sympathomimetics, beta2).Hypokalaemia\u00a0Potentially serious hypokalaemia may result from beta2 agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, and diuretics, and by hypoxia. Plasma-potassium concentration should therefore be monitored in severe asthma.", "side-effects": "Side-effects\u00a0\n(From 3.1.1.1 Selective beta2 agonists: British National Formulary)\nSide-effects\u00a0Side-effects of the beta2 agonists include fine tremor (particularly in the hands), nervous tension, headache, muscle cramps, and palpitation. Other side-effects include tachycardia, arrhythmias, peripheral vasodilation, myocardial ischaemia, and disturbances of sleep and behaviour. Paradoxical bronchospasm (occasionally severe), urticaria, angioedema, hypotension, and collapse have also been reported. High doses of beta2 agonists are associated with hypokalaemia (see Hypokalaemia above).", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2894.htm", "doses": ["By mouth (but use by inhalation preferred),\r\ninitially 2.5\u00a0mg 3 times daily for 1\u20132 weeks, then up to 5\u00a0mg 3 times\r\ndaily; child 1 month\u20137 years 75\u00a0micrograms/kg\r\n3 times daily; 7\u201315 years 2.5\u00a0mg 2\u20133 times daily", "By subcutaneous or slow intravenous injection, 250\u2013500\u00a0micrograms up\r\nto 4 times daily; child 2\u201315 years\r\n10\u00a0micrograms/kg to a max. of 300\u00a0micrograms", "By continuous intravenous infusion as a solution containing 3\u20135\u00a0micrograms/mL, 90\u2013300\u00a0micrograms/hour\r\nfor 8\u201310 hours; child 1 month\u201318 years,\r\ninitially 2\u20134\u00a0micrograms/kg as a loading dose, then 1\u201310\u00a0micrograms/kg/hour\r\naccording to response and heart rate (max. 300\u00a0micrograms/hour); high\r\ndoses with close monitoring", "By inhalation of powder (Turbohaler\u00ae), adult and child over 5 years, 500\u00a0micrograms (1 inhalation);\r\nfor persistent symptoms up to 4 times daily (but see Management of Chronic Asthma\r\ntable)", "By inhalation of nebulised solution (but see also Management of Acute Asthma table), 5\u201310\u00a0mg 2\u20134 times daily;\r\nadditional doses may be necessary in severe acute asthma; child under 5 years 5\u00a0mg 2\u20134 times daily, 5\u201312 years\r\n5\u201310\u00a0mg 2\u20134 times daily [unlicensed dose]", "Name[Bricanyl\u00ae (AstraZeneca) ] Tablets, scored, terbutaline\r\nsulphate 5\u00a0mg, net price 100- tab pack= \u00a34.09\nSyrup, sugar-free, terbutaline\r\nsulphate 1.5\u00a0mg/5\u00a0mL, net price 100\u00a0mL = \u00a32.00\nInjection, terbutaline\r\nsulphate 500\u00a0micrograms/mL, net price 1-mL amp = 30p; 5-mL\r\namp = \u00a31.40"], "pregnancy": "Pregnancy\u00a0see section 3.1"}, {"indications": "Indications\u00a0asthma and other conditions associated with reversible\r\nairways obstruction; premature labour (section 7.1.3)", "name": "TERBUTALINE SULPHATE Inhalation", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "3 Respiratory system", "3.1 Bronchodilators", "3.1.1 Adrenoceptor agonists", "3.1.1.1 Selective beta2 agonists", "TERBUTALINE SULPHATE", "Inhalation"], "cautions": "Cautions\u00a0\n(From 3.1.1.1 Selective beta2 agonists: British National Formulary)\nCautions\u00a0Beta2 agonists should be used with caution in hyperthyroidism, cardiovascular disease, arrhythmias, susceptibility to QT-interval prolongation, and hypertension. Beta2 agonists should be used with caution in diabetes\u2014monitor blood glucose (risk of ketoacidosis, especially when beta2 agonist given intravenously). Interactions: Appendix 1 (sympathomimetics, beta2).Hypokalaemia\u00a0Potentially serious hypokalaemia may result from beta2 agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, and diuretics, and by hypoxia. Plasma-potassium concentration should therefore be monitored in severe asthma.", "side-effects": "Side-effects\u00a0\n(From 3.1.1.1 Selective beta2 agonists: British National Formulary)\nSide-effects\u00a0Side-effects of the beta2 agonists include fine tremor (particularly in the hands), nervous tension, headache, muscle cramps, and palpitation. Other side-effects include tachycardia, arrhythmias, peripheral vasodilation, myocardial ischaemia, and disturbances of sleep and behaviour. Paradoxical bronchospasm (occasionally severe), urticaria, angioedema, hypotension, and collapse have also been reported. High doses of beta2 agonists are associated with hypokalaemia (see Hypokalaemia above).", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2898.htm", "doses": ["By mouth (but use by inhalation preferred),\r\ninitially 2.5\u00a0mg 3 times daily for 1\u20132 weeks, then up to 5\u00a0mg 3 times\r\ndaily; child 1 month\u20137 years 75\u00a0micrograms/kg\r\n3 times daily; 7\u201315 years 2.5\u00a0mg 2\u20133 times daily", "By subcutaneous or slow intravenous injection, 250\u2013500\u00a0micrograms up\r\nto 4 times daily; child 2\u201315 years\r\n10\u00a0micrograms/kg to a max. of 300\u00a0micrograms", "By continuous intravenous infusion as a solution containing 3\u20135\u00a0micrograms/mL, 90\u2013300\u00a0micrograms/hour\r\nfor 8\u201310 hours; child 1 month\u201318 years,\r\ninitially 2\u20134\u00a0micrograms/kg as a loading dose, then 1\u201310\u00a0micrograms/kg/hour\r\naccording to response and heart rate (max. 300\u00a0micrograms/hour); high\r\ndoses with close monitoring", "By inhalation of powder (Turbohaler\u00ae), adult and child over 5 years, 500\u00a0micrograms (1 inhalation);\r\nfor persistent symptoms up to 4 times daily (but see Management of Chronic Asthma\r\ntable)", "By inhalation of nebulised solution (but see also Management of Acute Asthma table), 5\u201310\u00a0mg 2\u20134 times daily;\r\nadditional doses may be necessary in severe acute asthma; child under 5 years 5\u00a0mg 2\u20134 times daily, 5\u201312 years\r\n5\u201310\u00a0mg 2\u20134 times daily [unlicensed dose]", "Name[Bricanyl\u00ae (AstraZeneca) ] Turbohaler\u00ae (= dry powder inhaler), terbutaline sulphate 500\u00a0micrograms/metered inhalation,\r\nnet price 100-dose unit = \u00a36.92. \r\n    Label:\r\n    Counselling, administration\nRespules\u00ae (= single-dose units for\r\nnebulisation), terbutaline sulphate 2.5\u00a0mg/mL,\r\nnet price 20 \u00d7 2-mL units (5-mg) = \u00a34.04"], "pregnancy": "Pregnancy\u00a0see section 3.1"}]